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Purposes: First, to evaluate outcome, the benefit of concurrent chemotherapy and prognostic factors in a cohort
of sixty-four high-grade glioma patients who underwent a second course of radiation therapy at progression.
Second, to validate a new prognostic score for overall survival after reirradiation of progressive gliomas with an
independent patient cohort.
Patients and methods: All patients underwent fractionated reirradiation with a median physical dose of 36 Gy.
Median planned target volume was 110.4 ml. Thirty-six patients received concurrent chemotherapy consisting in
24/36 cases (67%) of carboplatin and etoposide and in 12/36 cases (33%) of temozolomide. We used the Kaplan
Meier method, log rank test and proportional hazards regression analysis for statistical assessment.
Results: Median overall survival from the start of reirradiation was 7.7 ± 0.7 months. Overall survival rates at 6 and
12 months were 60 ± 6% and 24 ± 6%, respectively. Despite relatively large target volumes we did not observe any
major acute toxicity. Concurrent chemotherapy did not appear to improve outcome. In contrast, female gender,
young age, WHO grade III histology, favorable Karnofsky performance score and complete resection of the tumor
prior to reirradiation were identified as positive prognostic factors for overall survival. We finally validated a recent
suggestion for a prognostic score with our independent but small patient cohort. Our preliminary findings suggest
that its ability to discriminate between different prognostic groups is limited.
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Table 1 Characteristics of 64 patients treated for
recurrent high-grade gliomas using a second series of
radiotherapy with or without concurrent chemotherapy
Characteristic
Median age at Re-RT (years) 53.5
Range: age at Re-RT (years) 21.8 – 81.1
< 50 years at Re-RT 26/64 (40.6%)
≥ 50 years at Re-RT 38/64 (59.4%)
Male 34/64 (53.1%)
Female 30/64 (46.9%)
WHO IV 53/64 (82.8%)
WHO III 11/64 (17.2%)
Karnofsky performance score < 70 13/64 (20.3%)
Karnofsky performance score≥ 70 51/64 (79.7%)
Median time (RT to Re-RT) (months) 13.4
Range: time (RT to Re-RT) (months) 2.7 – 202.6
Time from RT to Re-RT≤ 12 months 21/64 (32.8%)
Time from RT to Re-RT > 12 months 43/64 (67.2%)
Concurrent chemotherapy 36/64 (56.3%)
Carboplatin/etoposide 24/64 (37.5%)
Temozolomide 12/64 (18.8%)
Complete resection before Re-RT 8/64 (12.5%)
Incomplete/no resection before Re-RT 56/64 (87.5%)
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Salvage treatment of progressive high-grade gliomas
(HGG) remains one of the most challenging tasks in
neuro-oncology [1,2]. Meanwhile, reirradiation has been
widely accepted as useful therapeutic option and adopted
in clinical routine [3]. The credit for this belongs to numer-
ous retrospective studies, which reported satisfactory sur-
vival rates and acceptable toxicity in the last two decades.
However, most of these studies included highly selected pa-
tients focussing on stereotactic reirradiation techniques
and the treatment of small tumor volumes. There is only
sparse data on reirradiation of large recurrent tumors
(Additional file 1: Table S1) [4-10]. Moreover, the benefit
of combining reirradiation with concurrent chemother-
apy is still elusive [6-8,11] (Additional file 2: Table S2).
Assuming significant benefit, what would be the best
choice for the chemotherapeutic agent? Temozolomide,
a drug which is administered to the vast majority of pa-
tients in first-line treatment or an alternative chemo-
therapy regimen? Our dataset is suitable to contribute
to the answers to these important questions. In a recent
review, the question which patients would be the best
candidates for reirradiation was addressed [12]. This
question should be subdivided into two aspects: First, in
which patients reirradiation is feasible with acceptable
toxicity and second, which patients benefit most from
reirradiation in terms of survival? To answer the second
question two requirements have to be met:
1. A cohort of reirradiated patients has to be compared
with a non-irradiated control group. In this context,
we eagerly await the results of the Radiation
Therapy Oncology Group (RTOG) 1205 randomized
phase II trial (concurrent bevacizumab and
reirradiation versus bevacizumab alone as treatment
for recurrent glioblastoma).
2. Given the confusing variety of factors determining
the outcome of progressive high-grade glioma
patients, a simple and reliable system is needed to
classify patients into subgroups with similar
prognosis. In future these subgroups may constitute
the basis for individual patient councelling and
clinical decision making (e.g., reirradiation, yes or
no?). A German research group recently suggested
such a classification system in the form of a
prognostic score based on three clinical factors
predicting overall survival after reirradiation.
However, although perfectly meeting the criterion of
simplicity its reliability still had to be validated with
an independent patient cohort [3]. In the present
analysis we specifically address outcome and toxicity
in progressive high-grade glioma patients with large
tumor volumes, the role of concurrent
chemotherapy, prognostic factors for overall survivaland the validation of a simple prognostic score with
an independent dataset.
Patients and methods
Sixty-four patients with recurrent high-grade gliomas
underwent reirradiation at our department from March
2005 to May 2012. Gender distribution was almost bal-
anced. Median age at the start of reirradiation was 53.4 years
(range: 21.8 – 81.1 years). Median time from the end of the
first radiotherapeutic treatment to the start of reirradiation
was 13.4 months (range: 2.7 – 202.6 months) (Table 1).
First-line treatment
Sixty-three patients (98.4%) underwent neurosurgical re-
section. All patients received radiotherapy with a median
total dose of 60 Gy (range: 36–60 Gy). 56/64 patients
(87.5%) received chemotherapy. In 47/56 cases (83.9%)
it consisted of temozolomide, which was combined in 2/
47 cases (4.3%) with cilengitide. 7/64 patients (10.9%)
received second-line chemotherapy and 2/64 patients
(3.1%) carmustine implants (gliadel wafers®) during
initial treatment.
Second-line treatment
Fourty-three patients (67.2%) underwent surgical resec-
tion or biopsy of the relapsed tumor before reirradiation.
In five of those patients even more than one surgery was
Table 2 Outcome of 64 patients treated for recurrent
high-grade gliomas using a second series of radiotherapy
with or without concurrent chemotherapy
Characteristic OS-6 (%) mOS (months) p=
< 50 years at Re-RT 73 ± 9 9.4 ± 1.4 0.015
≥ 50 years at Re-RT 50 ± 8 5.8 ± 1.4
Male 60 ± 9 7.7 ± 0.8 0.669
Female 59 ± 9 7.7 ± 1.7
WHO IV 55 ± 7 7.4 ± 1.4 0.009
WHO III 82 ± 12 11.2 ± 10.5
Karnofsky performance
score < 70
34 ± 14 5.0 ± 1.0 0.002
Karnofsky performance
score≥ 70
66 ± 7 8.1 ± 0.8
Time from RT to Re-RT≤
12 months
52 ± 11 6.9 ± 2.5 0.140
Time from RT to Re-RT >
12 months
63 ± 8 8.1 ± 1.1
No concurrent
chemotherapy1
52 ± 10 6.6 ± 2.9 0.001 (3 vs 2)
Carboplatin/etoposide2 54 ± 10 6.7 ± 1.3 0.006 (3 vs 1)
Temozolomide3 92 ± 8 27.0 ± 17.6 0.455 (2 vs 1)
Complete resection
before Re-RT
100 17.5 ± 3.4 0.034
Incomplete/no resection
before Re-RT
55 ± 7 7.4 ± 1.3
OS-6 overall survival rate at six months, mOS median overall survival (months).
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was achieved. All patients underwent reirradiation with
a median total dose of 36 Gy (range: 30.0 Gy -
40.05 Gy). Fraction doses ranged from 2.0 to 5.0 Gy.
Generally, outpatients received 5, hospitalized patients
6 fractions a week. In 58/64 patients (90.6%) conven-
tional 3D-conformal radiotherapy was performed. In
contrast, 6/64 patients (9.4%) were treated with stereo-
tactic 3D-conformal radiotherapy.
Gross tumor volume (GTV) was the postsurgical
cavity or the macroscopic tumor as seen on pre-/post-
operative MRI (enhanced T1 and/or FLAIR/T2). For
conventional radiotherapy planning clinical target vol-
ume (CTV) was defined as GTV plus a margin of 5 mm
and planned target volume (PTV) as CTV plus a mar-
gin of 3 – 5 mm.
Median physical total dose of reirradiation was 36.0 Gy
(range, 30.0 – 40.05 Gy). Doses per fraction ranged from
2.0 – 5.0 Gy. We used the linear quadratic model to calcu-
late the biologically effective dose (BED) and the normal-
ized total dose (NTD) of each radiation regimen. The
BED was calculated according to the following relation-
ship: BED = nd (1 + d/[α/β]) [Gy], with d = fraction dose
[Gy], n = number of fractions, nd = D = total physical dose
[Gy], and α/β = tissue repair capacity [Gy]. For tumor ef-
fects an α/β value of 10 Gy and for normal brain tissue an
α/β value of 3 Gy were assumed. In a recent estimation of
radiobiologic parameters for malignant gliomas a median
α/β value of 9.32 Gy was reported [13]. The BED values
were converted to normalized total dose (NTD) values,
with NTD being defined as the total dose delivered in
2.0-Gy fractions. The NTD is the ratio of the BED and
the relative effectiveness (RE) value. RE = (1 + d/[α/β]),
d = 2 Gy [14-16]. The median NTD(α/β = 10) was 39.0 Gy
(range, 32.5 – 42.29 Gy). The median NTD(α/β = 3) was
43.2 Gy (range, 36.0 – 48.0 Gy).
Median PTV size was 110.4 ml (range 1.8 ml –
378 ml). In 36 cases chemotherapy was given simultan-
eously to reirradiation. In 12/36 cases (33%) it consisted
of temozolomide (75 mg/m2/day) and in 24/36 cases
(67%) of carboplatin (100 mg/m2/day) and etoposide
(120 mg/m2/day) (Table 2). In 28/36 patients chemo-
therapy was continued after reirradiation. 9/64 patients
started with chemotherapy after the end of reirradiation
(7 with temozolomide and 2 with carboplatin/etoposide).
Twelve patients additionally received another chemo-
therapy regimen and six patients again underwent sur-
gery after reirradation.
Histology at primary diagnosis
In one patient the initial histological diagnosis was not
available. Besides that, WHO grade III gliomas were di-
agnosed in 14/64 patients (21.9%) and WHO grade IV
glioblastomas/gliosarcomas in 49/64 patients (76.6%).Histology at reirradiation
Second surgery and histological assessment revealed
WHO grade III gliomas in 4/43 patients (9.3%) and
WHO grade IV gliomas in 39/43 patients (90.7%).
Statistics
Survival times were calculated from the start of reir-
radiation. For progression-free survival (PFS), events
were defined as radiographic or clinical evidence for
progression or death by any cause, whatever happened
first. Death resulting from any cause was defined as
event for overall survival (OS). The latest histological
grading (according to the WHO classification of brain
tumors, 2007) was used for uni- and multivariate ana-
lyses. The Kaplan-Meier method was used to estimate
OS and PFS.
Univariate analyses
Kaplan Meier survival estimates were compared by
means of the log rank test. Differences were defined if
the p-value was less than 0.05. Aditionally, the influence
of continous variables (size of the planned target volume,
age and Karnofsky performance score at reirradiation)
on OS was assessed using cox proportional hazards re-
gression analysis.
Figure 1 Progression-free and overall survival of 64 patients
treated for recurrent high-grade gliomas using a second series
of fractionated external beam radiotherapy with or without
concurrent/subsequent chemotherapy.
Figure 2 Influence of the PTV size on overall survival
after reirradiation.
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Cox regression models with backward stepwise selection
(inclusion criterion: p-value of the score test ≤ 0.05, exclu-
sion criterion: p-value of the likelihood ratio test ≥ 0.10)
were used to analyse the prognostic value of age at the
start of reirradiation, Karnofsky performance score (both
continuous), sex, extent of prior resection, WHO grading
and concurrent chemotherapy on OS [17]. For the final
models, the estimated hazard ratios of the selected ex-
planatory variables with respective 95% confidence inter-
vals (CI) and p-values of the likelihood ratio test are given.
All analyses were performed on SPSS system, version 20.
Prognostic score for survival after reirradiation
To estimate patients’ prognosis a sum of the following
values is calculated: for histology, glioblastoma is rated
as 2 and WHO grade III tumors as 1. With respect to
age, patients younger than 50 are given 0 points and age
50 or older is scored with 1. Time between initial
radiotherapy and reirradiation is counted as 0 if 12 or
more months and as 1 if the time interval is less than
12 months. A summative value of 1 represents favorable,
of two intermediate and of 3/4 poor prognosis [3].
Results
Outcome
At a median follow-up time of 7.5 months across all pa-
tients (range: 1.0 – 51.4 months), 60/64 patients (93.8%)
experienced a progression and 55/64 patients (85.9%)
died. Median PFS was 4.3 ± 0.9 months. PFS rates at 6 and
12 months were 33 ± 6% and 10 ± 4%, respectively. Median
OS was 7.7 ± 0.7 months. OS rates at 6 and 12 months
were 60 ± 6% and 24 ± 6%, respectively (Figure 1).
Prognostic factors for OS in univariate analysis
Categorical variables, Kaplan Meier method, log rank test
Neither gender (p = 0.669) nor concurrent chemotherapy
with carboplatin/etoposide (p = 0.294), the PTV size
(cut-off 110 ccm) (Figure 2) or a long period of time be-
tween the end of initial radiotherapy and reirradiation
(cut-off 1 year) (p = 0.140) did impact OS. In contrast,
univariable survival analyses identified younger age (cut-off
50 years) (p = 0.015), WHO grade III histology (p = 0.009),
favorable Karnofsky performance score (cut-off 70%) (p =
0.002), complete resection prior to reirradiation (p = 0.034)
and concurrent chemotherapy with temozolomide (vs. no
concurrent chemotherapy: p < 0.006 and vs. concurrent
chemotherapy with carboplatin/etoposide: p = 0.001) as
positive prognostic markers (Figure 3 and Table 2).
Continous variables, Cox proportional hazards regression
analysis
On univariate cox regression analyses age (p = 0.005,
hazard ratio = 1.03 per year, 95% CI: 1.01-1.05) and theKarnofsky performance score (KPS) (p = 0.001, hazard
ratio = 0.75 per 10 points, 95% CI: 0.64-0.89) influenced
OS, whereas the size of the PTV did not (p = 0.607).
One year of age increased the risk of death hence by 3%
and 10 years of age by 34% (1.0310 = 1.34). Accordingly,
the risk of death was reduced by 25% if the KPS in-
creased by 10 percent (0.9710 = 0.74).
Prognostic factors for overall survival in multivariate (cox
proportional hazards regression) analysis
On multivariate analysis, female gender, young age, WHO
grade III histology, favorable Karnofsky performance score
and complete resection prior to reirradiation were identi-
fied as positive prognostic markers. In contrast concurrent
chemotherapy, the time interval between first-line and
Figure 3 Influence of concurrent chemotherapy on overall
survival after reirradiation.
Figure 4 Re-assessment of the prognostic score recently
suggested by Combs et al. to predict overall-survival after
reirradiation of relapsed HGG.
Table 3 Acute toxicity during radio (chemo)therapy (all
patients, patients with PTV ≤ 110 ml and patients with
PTV > 110 ml)
All patients
(n = 64)
PTV ≤ 110 ml
(n = 32)
PTV > 110 ml
(n = 32)
Headache (≤ II° CTC) 7/64 (10.9%) 2/32 (6.3%) 5/32 (15.6%)
Nausea/vomiting
(≤ II° CTC)
4/64 (6.3%) 3/32 (9.3%) 1/32 (3.1%)
Seizures (≤ II° CTC) 5/64 (7.8%) 2/32 (6.2%) 3/32 (9.3%)
Skin reaction (≤ II° CTC) 7/64 (10.9%) 3/32 (9.3%) 4/32 (12.5%)
Mucosa reaction
(≤ II° CTC)
2/64 (3.1%) 1/32 (3.1%) 1/32 (3.1%)
Ear toxicity (≤ II° CTC) 0/64 (0%) 0/64 (0%) 0/64 (0%)
Infections (≤ II° CTC) 3/64 (4.6%) 1/32 (3.1%) 2/32 (6.3%)
PTV planned target volume, CTC common toxicity criteria version 3.0.
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influence outcome.
Reassessment of the prognostic score for overall survival
after reirradiation of relapsed gliomas
We furthermore tried and validated the prognostic score
recently generated by Combs et al. [3] to estimate overall
survival after reirradiation of recurrent gliomas. For this
purpose, we first subdivided our patient cohort into four
different prognostic groups. Then, by means of the
Kaplan-Meier method and the log rank test, we com-
pared the respective survival curves with each other. We
did not observe significant differences (p < 0.05) in over-
all survival between all prognostic groups. Only patients
in the most favorable prognostic group (1) (young age +
favorable WHO grading + good general condition) did
significantly better (Figure 4).
Toxicity
All patients completed radiotherapy, which, in general,
was tolerated well. No major acute toxicities were ob-
served (grad III/IV toxicities according to common tox-
icity criteria for adverse events CTCAE v3.0) (Table 3).
We did not observe any case of radiation necrosis, how-
ever, posttherapeutic MRI controls were not performed
routinely, hence clinically asymptomatic lesions could
not be excluded. One patient died during the third cycle
of maintenance chemotherapy consisting of carboplatin/
etoposide due to severe hematologic aplasia.
Discussion
General aspects
As stated above, reirradiation has been widely accepted
as useful therapeutic option in the salvage treatment ofprogressive high-grade gliomas. The National Compre-
hensive Cancer Network (NCCN) guidelines for recur-
rent or progressive glioblastoma multiforme recommend
to “consider”a second course of radiotherapy in local re-
currence, especially if there was a long interval since
prior irradiation and/or if there was a good response to
first-line treatment [18]. A recent review concluded that
patients with a KPS greater than 60%, progression more
than 6 months from time of surgery and a tumor size of
up to 40 mm were the best candidates [12]. Median KPS
in our cohort was 90% (range 40 – 100%) and median
time interval between initial surgery and first progres-
sion 13 months (range, 2 – 145 months). However, pre-
suming spherical tumor shape and a safety margin of
1.0 cm from GTV to PTV, at least the latter criterion
may not have been fulfilled in approximately half of our
patients. This is also reflected by the fact that most of
our patients (91%) underwent a second course of conven-
tional 3D-conformal radiotherapy instead of stereotactic
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(≤ 4 cm).
Outcome in terms of overall survival and toxicity
The overall survival after reirradiation in our cohort was
relatively poor but comparable to previous studies. Fo-
cussing on our glioblastoma patients only, overall sur-
vival at 12 months was 19 ± 6%. In contrast, a recent
review summarizing the data of 14 reirradiation studies
with a total of 300 glioblastoma patients reported sur-
vival rates at 12 months ranging between 18 and 48%.
However, most of these studies only included highly se-
lected patients with small tumor volumes suitable for
stereotactic radiotherapy, brachytherapy or radiosurgery
and patient numbers were small [19].
The acute radiation-induced toxicity in our cohort
during and shortly after the second course of radiation
therapy was negligibly low (Table 3). Moreover, to the
best of our knowledge, radiation necrosis did not occur
in any patient in the further course of disease. This fits
well with the conclusions drawn by two important re-
views on normal brain tissue tolerance which stated that
a 10% incidence of radiation-induced necrosis has to be
expected at a cumulative normalized total dose (fraction
dose, 2 Gy; α/β, 3 Gy) of 90 Gy, but just 1–2 years after
irradiation, i.e., in progressive high-grade glioma patients
after the expected survival time. Unfortunately, the im-
pact of the planning target volume (PTV) on the risk for
necrosis was not elaborately discussed [16,20].
Role of concurrent chemotherapy
In our cohort concurrent chemotherapy with temozo-
lomide was associated with longer OS in uni- but not in
multivariable analysis. Concurrent chemotherapy with
carboplatin/etoposide did not influence OS. This may
reflect that young patients in good general condition, i.e.
with a more favorable prognosis, tended to receive out-
patient radiotherapy with concurrent oral temozolomide
whereas older patients in worse general condition tended
to be hospitalized for simultaneous radiochemotherapy
with carboplatin/etoposide or for reirradiation only. Al-
though numerous studies on concurrent radiochemother-
apy as salvage treatment in relapsed high-grade gliomas
have been published so far, there is at best little evidence
for a favorable impact on OS. We identified four studies
evaluating retrospectively the potential benefit of concur-
rent/subsequent chemotherapy by comparison of survival
times (Additional file 2: Table S2). In the analysis performed
by Ernst-Stecken et al. chemotherapy did not influence sur-
vival. However, the number of patients was limited (n = 15)
and the statistical analysis depicts methodological weak-
nesses, as survival times were compared by the Kaplan
Meier method and log rank test instead of time-dependent
cox regression [11,21]. Fokas et al. treated 53 patients withrecurrent glioblastoma multiforme by hypofractionated
stereotactic radiotherapy. Twenty-five patients received dif-
ferent chemotherapy regimens at the time of reirradiation
(8× temozolomide, 9× nimustine & teniposide (ACNU/VM
26), 5× procarbazine & vincristine (PCV), 3× sequential
treatment with temozolomide/nitroseureas). Addition of
chemotherapy did not affect survival (p = 0.1466) [7]. A
similar analysis was done by Fogh et al. who reirradiated
147 recurrent high-grade gliomas. 48 patients received dif-
ferent regimes of concomitant chemotherapy. Cox regres-
sion models were used to analyze survival outcomes.
There was no significant benefit of chemotherapy in this
population when analysis was controlled for other prog-
nostic factors [6]. Grosu et al. reported a series of 44 pa-
tients, in which 29 patients (66%) had received one to two
cycles temozolomide before and four to five cycles after
reirradiation. In contrast to the previously mentioned
studies, temozolomide was associated with better survival
in the uni- and multivariate model [8].
Prognostic factors
Our analysis demonstrated, that there is a variety of
factors that have prognostic relevance for overall survival
after salvage treatment. These factors are discussed in
the following section.
Target volume
We identified seven studies assessing the influence of
the size of the target volumes on survival. Results were
partly conflicting. Approximately 500 patients had been
taken into account in total. Only one study reported a
significant correlation between smaller gross/planned
target volumes and better survival on multivariate ana-
lysis [6]. Two other studies found a tendency towards
better survival in patients with smaller PTVs on univari-
ate analysis [9,10]. According to the remaining four ana-
lyses the size of the target volumes (1× GTV, 3× PTV)
was not associated with survival differences [4,7,8,22]. In
our cohort the size of the PTV did not influence sur-
vival. Apart from Henke et al. and Bartsch et al. the pre-
viously mentioned groups used stereotactic radiotherapy
techniques and irradiated much smaller PTVs (range of
median PTVs 15 ml [10] – 50 ml [23]) than we did. We
used stereotactic techniques only in exceptional cases.
Median PTV was 110.4 ml. Nevertheless we did not
observe major toxicities. Moreover median OS in our
patient cohort (7.7 months) seems comparable to the OS
observed in other series (range of median OS 7 months
[22] – 16 months (only WHO grade III) [5]) taking into
account the favorable influence of lower WHO grading.
Gender
Most previous studies did not assess the possible influ-
ence of gender on OS after reirradiation of high-grade
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issue [23-26]. None of them found an impact of gender,
however, in all cases only univariable analysis had been
performed. In contrast to our preliminary findings in
univariate analysis which were in line with the above
mentioned results, multivariate (cox proportional haz-
ards regression) analysis surprisingly revealed a positive
impact of female gender on OS in our cohort. Without
doubt our findings need to be reassessed by other
working groups.
Age and Karnofsky performance score
In our study young age and a favorable Karnofsky per-
formance score positively influenced OS in both uni-
and multivariable analysis. These findings are in agree-
ment with the literature [1,6,7,24,27]. Nevertheless, at
least in multivariate analysis, some authors could not
confirm the positve prognostic value of young age and a
favorable KPS [8,9].
WHO grading at latest available histology
In our cohort WHO grade III tumors were associated
with better OS after reirradiation on uni- and multivari-
able analyses. However, the results of previous studies
concerning the favorable impact of WHO III grading
are conflicting. Some authors confirm our results
[1,10,24,26-28] whereas others do not [6,8,11,19,23,25].
One study reported that median survival time from the
start of reirradiation was 10 months for patients with
grade III tumors and 11 months in grade IV patients.
However, the difference did not reach statistical signifi-
cance [6].
Time intervall between initial radiotherapy and
reirradiation
In our cohort the time intervaI between initial radiother-
apy and reirradiation did not impact OS on uni- and
multivariate analysis. These findings are in line with the
results of six previous studies [3,9,10,24,27,29], at least
on multivariate analysis. Interestingly all authors chose a
relatively short time interval (range 10 – 20 months) as
cut-off for statistical assessment. In the analysis of Fogh
et al. a time interval < 6 months was correlated with bet-
ter survival on multivariate analysis [6]. In contrast in
two series a longer time interval was associated with
better survival on both uni- and multivariable analysis.
However, here the authors chose relatively long time
intervals as cut-off for statistical assessment (range
24 months – 36 months) [8,19].
Extent of salvage surgery
The role of salvage surgery in recurrent or progressive
high-grade glioma is controversially discussed. Some au-
thors point out that the potential benefit achieved bytumor resection may be limited by perioperative morbid-
ity and mortality [5,9,30-32]. In contrast, Bartsch et al.
observed an improvement of survival if surgery was a
component of salvage treatment [22]. In our cohort fourty-
three patients underwent surgery before reirradiation. Sur-
vival was not improved (p = 0.479). This is in line with data
of some other groups [7,10,29]. However, upon closer
examination the extent of surgery affected outcome. Pa-
tients with complete resection depicted a median OS of
17.5 months whereas in patients with incomplete or with-
out resection median survival was only 7.4 months (p =
0.034). In summary, our data suggests that second surgery
is of limited use if complete resection cannot be achieved.
Prognostic score
The most convincing way to demonstrate the success of
a possible prognostic score is to prove its ability to dis-
criminate different prognostic groups in a patient cohort
which is independent from its development [33,34].
However, solely for the generation of a prognostic score,
a very large number of patients is needed. Simon and
Altman recommended at least ten times the number of
events (e.g. deaths) in comparison to the number of
potential prognostic factors as a “reasonable standard”
[35]. Reirradiation of high-grade gliomas is rarely
performed. Thus, it makes sense that several major cen-
ters are involved in the generation and validation of a
scoring system to predict the benefit of reirradiation in
high-grade gliomas. Combs et al. encouraged us kindly
to validate the recently presented Heidelberg prognostic
score [3] with our independent cohort. However, the sub-
classification of our patients into the four scoring groups
did not demonstrate a convincing correlation with overall
survival after reirradiation in visual validation and in log
rank test (Figure 4). This is most likely due to the small
amount of patients included into the analysis, as well the
fact that only patients with high-grade histology were in-
cluded. It is known that histology plays a major prog-
nostic role, and the score was established in a patient
cohort with different histologies. Since the focus of the
present analysis is the evaluation of the outcome of pa-
tients with a high-grade gliomas, the score might not
help to distinguish between this subgroups of patients,
underlining the importance of histological classification.
Conclusions
Outcome of our patients was comparable to survival rates
reported in previous studies. Even in case of large target
volumes (PTV > 110 ml, Table 3) reirradiation seems to be
feasible. In the setting of reirradiation the benefit of con-
current chemotherapy needs to be determined. A reliable
prognostic score might be the most robust way for prog-
nostication. We validated a recently established prognostic
score [3] with our independent but relatively small patient
Scholtyssek et al. Radiation Oncology 2013, 8:161 Page 8 of 9
http://www.ro-journal.com/content/8/1/161cohort. Our preliminary findings suggest that its ability to
discriminate between different prognostic groups appears
to be limited in our cohort. However, a reassessement in a
much larger cohort seems to be necessary.Ethical statements
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